Daniel Von Hoff

Daniel Von Hoff

Daniel D. Von Hoff, M.D., F.A.C.P. is a medical oncologist and oncology drug developer who has conducted national clinical trials with more than 200 new antineoplastic and biologic agents.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. Dr. Von Hoff and his colleagues have conducted early clinical investigations of most of the new agents that have been approved for cancer treatment in the United States in the last two decades, including gemcitabine, docetaxel, paclitaxel, topotecan, irinotecan, fludarabine, mitoxantrone, dexrazoxane, nab-paclitaxel, and multiple others.

At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for individual patients with cancer.

For more than 30 years, Dr. Von Hoff has dedicated his time and experience to the study of cancer and treatment methods. Among his significant activities:

• International leadership in bringing to patients new anti-cancer agents – many of which have been shown to increase patient survival.
• Study of pancreatic and other forms of cancer.
• Dedication to teaching the next generation of both basic and clinical students.
• Entrepreneurial research efforts, which have led to 12 patents.

Dr. Von Hoff most recently served a six-year term on President Bush's National Cancer Advisory Board (June 2004 - March 2010) and has served on the FDA’s Oncology Advisory Committee. He is the past President of the American Association for Cancer Research (the largest cancer research organization in the world), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.